Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambelli

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Journal for Immunotherapy of Cancer|November 28, 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, et al.
The Oncologist|December 28, 2020
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 PandemicAlberto Zambelli, Lorenzo Chiudinelli, Vittoria Fotia, et al.
Tumori|December 15, 2025
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switchingMariangela Gaudio, Anna Floreani, Greta Schivardi, et al.
British Journal of Cancer|January 11, 2017
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasmsMichela Romano, Matteo Giovanni Della Porta, Anna Gallì, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
European Journal of Endocrinology|July 26, 2024
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapiesMaria Francesca Birtolo, Rebecca Pedersini, Andrea Palermo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Cancers|February 12, 2021
Analysis of Italian <i>BRCA1/2</i> Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern ItalyGisella Figlioli, Arcangela De Nicolo, Irene Catucci, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Journal for Immunotherapy of Cancer|November 28, 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, et al.
The Oncologist|December 28, 2020
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 PandemicAlberto Zambelli, Lorenzo Chiudinelli, Vittoria Fotia, et al.
Tumori|December 15, 2025
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switchingMariangela Gaudio, Anna Floreani, Greta Schivardi, et al.
British Journal of Cancer|January 11, 2017
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasmsMichela Romano, Matteo Giovanni Della Porta, Anna Gallì, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
European Journal of Endocrinology|July 26, 2024
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapiesMaria Francesca Birtolo, Rebecca Pedersini, Andrea Palermo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Cancers|February 12, 2021
Analysis of Italian <i>BRCA1/2</i> Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern ItalyGisella Figlioli, Arcangela De Nicolo, Irene Catucci, et al.
Pageof 17